Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Revlixen 10 mg & 25 mg Capsules
Lenalidomide 10mg & 25mg capsules – Everest Pharmaceuticals Ltd.
Approved for adults with multiple myeloma (MM) — in combination with dexamethasone, and as maintenance therapy after autologous stem cell transplant — and for myelodysplastic syndromes (MDS) with deletion 5q (del(5q)) cytogenetic abnormality, and for certain mantle cell lymphoma (MCL) and follicular lymphoma patients (in combination with rituximab).
- Clinical outcomes at a glance
25.5 mo
Median progression-free survival, multiple myeloma maintenance after transplant (CALGB 100104)
~67%
Of del(5q) MDS patients achieved transfusion independence (MDS-003/004 trials)
20+ yrs
In clinical use — fundamentally changed multiple myeloma treatment since 2005 FDA approval
28-day
Cycle: 21 days on, 7 days off (combination regimen) — varies by indication
- Am I a candidate? — Take Decesion
1
Confirm diagnosis and specific indication
Multiple myeloma (newly diagnosed or maintenance after transplant), del(5q) MDS confirmed by cytogenetic testing, or relapsed/refractory mantle cell or follicular lymphoma with rituximab — each has a distinct dosing regimen.
2
Enroll in the REMS program and complete pregnancy/contraception requirements
Mandatory enrollment for prescriber, pharmacy, and patient. Females of reproductive potential require two negative pregnancy tests before starting and must use two reliable contraception methods throughout treatment and for 4 weeks after stopping.
3
Assess blood clot risk and baseline blood counts
History of DVT/PE, smoking, hypertension, hyperlipidemia, or prior thromboembolic events significantly raises risk — anti-thrombotic prophylaxis (aspirin or anticoagulant) is typically required. Baseline CBC needed given hematologic toxicity risk.
4
Discuss goals of care and kidney function-based dosing
Dose must be adjusted for reduced kidney function (CLcr <60 mL/min) since lenalidomide is primarily kidney-excreted. Weigh survival/remission benefit against REMS commitment, clot prevention plan, and regular monitoring requirements.
Important safety information — boxed warning (three parts): (1) Embryo-fetal toxicity — lenalidomide is a thalidomide analogue that causes severe birth defects or fetal death; absolutely contraindicated in pregnancy and available only through the REMS program. (2) Hematologic toxicity — can cause significant neutropenia and thrombocytopenia requiring regular blood count monitoring. (3) Venous and arterial thromboembolism — significantly increased risk of DVT, pulmonary embolism, heart attack, and stroke, particularly when combined with dexamethasone; anti-thrombotic prophylaxis is recommended.
- common side effects to know
- Diarrhea / fatigue (≥20%)
- Muscle cramps / back pain
- Peripheral edema / rash
- Anemia / constipation
- Severe neutropenia / thrombocytopenia
- Blood clots (DVT/PE), heart attack, stroke
- Trust & expertise
- FDA Approved 2005 (MDS)
- FDA Approved 2006 (MM)
- NCCN Myeloma / MDS Guidelines
- CALGB 100104 / MDS-003/004
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
“Lenalidomide has been a foundational drug in myeloma treatment for nearly two decades — as induction therapy, and especially as maintenance after transplant, where it has meaningfully extended progression-free survival. The REMS program and clot prevention plan are not bureaucratic hurdles — they directly address lenalidomide’s most serious risks, and patients who understand why these steps exist tend to navigate treatment with more confidence.”
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
Ready to discuss Tagrisso with your care team?
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Questions to ask my healthcare provider
Here are key questions to bring to your hematologist — given lenalidomide’s three-part boxed warning and REMS requirement, the pregnancy/contraception plan and blood clot prevention strategy deserve as much attention as the practical dosing questions.
Before confirming Revlixen (lenalidomide) as your treatment
- Which specific condition am I being treated for — multiple myeloma (combination or maintenance), del(5q) MDS, or lymphoma — and what dose and schedule does that correspond to?
- What prior treatments have I had, and why is lenalidomide being recommended at this point?
- Is this being used in combination with dexamethasone or another agent, or as monotherapy?
- Are there clinical trials I should know about?
About the REMS program — required before the first dose
- What does enrolling in the REMS program (or its local equivalent) actually involve for me as a patient — paperwork, education modules, monthly check-ins?
- How quickly can enrollment happen, and does this delay when I can start treatment?
- What ongoing requirements does the REMS program have throughout treatment — surveys, pharmacy pickup restrictions, prescription renewal timing?
About pregnancy risk and contraception — non-negotiable for anyone of childbearing potential
- What are the two required negative pregnancy tests before starting, and how far apart are they done?
- What two forms of contraception are required, and do I need to start them before or simultaneously with treatment?
- How long after stopping lenalidomide do I need to continue contraception?
- For male patients: what precautions are required regarding condom use with partners who could become pregnant, even after a vasectomy?
- What happens if a pregnancy occurs while on this medication — what is the immediate emergency response?
About blood clot risk — the thromboembolism warning
- Given my personal history, am I considered higher risk for blood clots — do I have any history of DVT, PE, heart attack, stroke, smoking, hypertension, or high cholesterol?
- Will I be started on aspirin or a stronger blood thinner as prophylaxis, and which one, and why?
- What are the early warning signs of a blood clot — leg swelling or pain, sudden shortness of breath, chest pain — that require emergency care?
- If I develop a blood clot while on lenalidomide, does treatment stop permanently or can it resume later?
About blood count monitoring
- How often will my complete blood count be checked, especially in the first weeks?
- What neutrophil or platelet count would trigger a dose interruption or reduction?
- What symptoms — fever, unusual bruising or bleeding, signs of infection — should prompt an urgent call?
About kidney function and dosing
- What is my current kidney function, and does it require a reduced starting dose?
- Will my kidney function be monitored throughout treatment, since this affects how the dose may need to change?
About the cycle schedule
- Can you walk me through the specific on/off schedule for my regimen — which days I take it, and for how many days in each cycle?
- Does it matter if I take it with or without food, and at what time of day?
- What should I do if I miss a dose?
- How long is the total expected duration of treatment — fixed number of cycles, or ongoing maintenance?
About managing common side effects
- Should I have anti-diarrheal medication on hand given how common diarrhea is?
- What can help with the fatigue, and is there a pattern to when it’s worst during the cycle?
- Are muscle cramps something I should mention right away, or are they expected and self-limiting?
- What does the peripheral edema look like, and when does it need attention?
About second primary malignancies — a longer-term consideration
- I understand there’s a recognized risk of second cancers (including leukemia or MDS) with long-term lenalidomide use — how is this monitored, and how does it factor into decisions about treatment duration, especially for maintenance therapy?
About my specific situation
- Does my age or any other medical conditions change my monitoring intensity?
- How does lenalidomide interact with my other current medications?
- If I’m currently on any other anticoagulant or antiplatelet medication, how does that interact with the recommended clot prophylaxis?
About the longer road
- How will we know if this is working — specific lab markers, bone marrow findings, or imaging depending on my diagnosis?
- If lenalidomide stops working or becomes intolerable, what would be considered next — pomalidomide, a different drug class, or another approach?
- Are there patient assistance programs through Bristol Myers Squibb if cost or REMS-related access is a concern?
A practical tip: Because the REMS enrollment and the pregnancy/contraception requirements must be completed before the first prescription can even be filled, it’s worth asking specifically what the realistic timeline looks like from your first appointment to your first dose — so you’re not caught off guard by administrative steps that, while essential for safety, can take longer than the clinical decision itself.
compare with other therapies
Lenalidomide and pomalidomide are both immunomodulatory drugs (IMiDs) in the same chemical family as thalidomide, and unlike most of our comparisons, these two are typically used sequentially rather than as alternatives at the same decision point — pomalidomide was specifically developed to work in patients who have already become resistant to lenalidomide.
What they are and how they relate
| Lenalidomide (Revlixen ) | Pomalidomide (Pomalyst) | |
|---|---|---|
| Drug class | Immunomodulatory drug (IMiD), thalidomide analogue | Immunomodulatory drug (IMiD), thalidomide analogue |
| Generation | 2nd-generation IMiD | 3rd-generation IMiD |
| Potency | Reference | More potent in vitro than lenalidomide and thalidomide |
| Approved | 2005 (MDS); 2006 (MM) | 2013 |
| Typical position | Earlier lines — induction, maintenance after transplant | Later lines — after lenalidomide and a proteasome inhibitor have failed |
| Manufacturer | Bristol Myers Squibb (Celgene) | Bristol Myers Squibb (Celgene) |
Pomalidomide retains activity against myeloma cells that have become resistant to lenalidomide — this is its central clinical purpose. It works through the same general immunomodulatory mechanism (binding cereblon, a protein involved in targeted protein degradation) but with structural differences that allow it to overcome at least some lenalidomide-resistance mechanisms.
Where each fits in the treatment sequence
Lenalidomide is typically used:
- As part of initial induction therapy for newly diagnosed multiple myeloma (often combined with bortezomib and dexamethasone, or similar combinations)
- As maintenance therapy after autologous stem cell transplant — this is one of its most well-established roles, supported by CALGB 100104 and other trials showing significant progression-free survival benefit
- In early relapse settings, often combined with dexamethasone
Pomalidomide is typically used:
- After a patient’s myeloma has progressed on or become refractory to lenalidomide
- Often in combination with dexamethasone (Pom-Dex), and increasingly with newer agents like daratumumab or isatuximab (anti-CD38 monoclonal antibodies) in three-drug combinations
- In patients who have also received a proteasome inhibitor (bortezomib or carfilzomib) previously
This sequential relationship means that for most patients, the relevant question isn’t “which one should I start with” but rather “I’m already on lenalidomide and it’s stopped working — should pomalidomide be next.”
Efficacy in the relapsed/refractory setting
The MM-003 trial, which led to pomalidomide’s approval, compared pomalidomide plus low-dose dexamethasone against high-dose dexamethasone alone in patients who had already failed both lenalidomide and bortezomib. Pomalidomide plus dexamethasone showed significantly improved progression-free survival and overall survival compared to high-dose dexamethasone alone — establishing its value specifically in this heavily pretreated, lenalidomide-refractory population.
This is an important distinction from a head-to-head comparison: pomalidomide wasn’t tested against lenalidomide directly in newly diagnosed patients, because that’s not the clinical question it was designed to answer. It was tested in patients for whom lenalidomide was already known not to be working.
Side effect comparison — broadly similar class, some differences in degree
| Lenalidomide | Pomalidomide | |
|---|---|---|
| Neutropenia | Common | More pronounced — often more significant cytopenias |
| Thrombocytopenia | Common | Present, generally less prominent than neutropenia |
| Venous thromboembolism | Significantly increased risk with dexamethasone | Similarly increased risk — same boxed warning |
| Embryo-fetal toxicity | Boxed warning — REMS required | Same boxed warning — POMALYST REMS required |
| Fatigue | Common | Common |
| Peripheral neuropathy | Less prominent than other myeloma drugs | Less prominent |
| Second primary malignancies | Recognized risk with long-term use | Recognized risk, similar class concern |
Both drugs share the same three-part boxed warning structure (embryo-fetal toxicity, hematologic toxicity, venous thromboembolism) and both require their own REMS program — Pomalidomide’s REMS program is essentially structured the same way as lenalidomide’s, given the shared mechanism and shared teratogenic risk.
The most clinically notable difference is that neutropenia tends to be more pronounced with pomalidomide, often requiring more proactive use of growth factor support (filgrastim or similar) and closer blood count monitoring, particularly in heavily pretreated patients whose bone marrow reserve is already compromised from prior therapies.
Dosing differences
| Lenalidomide | Pomalidomide | |
|---|---|---|
| Typical dose | 25mg once daily, days 1-21 of 28-day cycle (combination); 10mg for maintenance | 4mg once daily, days 1-21 of 28-day cycle |
| Kidney function adjustment | Required — significant renal excretion | Less dependent on kidney function — different elimination pathway, making it an option for some patients with renal impairment where lenalidomide dosing is complicated |
This kidney function difference is practically meaningful: multiple myeloma frequently causes kidney damage (from light chain deposition or other mechanisms), and patients with significant renal impairment may have an easier time with pomalidomide dosing than with lenalidomide, which requires more careful dose reduction based on creatinine clearance.
Cross-resistance — what “lenalidomide-refractory” actually means for pomalidomide
An important nuance: while pomalidomide retains activity in many lenalidomide-refractory patients, response rates in this setting (typically 30-35% overall response in heavily pretreated populations) are generally lower than the response rates lenalidomide itself achieved when used earlier in treatment. This reflects the general pattern in myeloma treatment where each subsequent line of therapy tends to produce somewhat lower response rates than the line before, as the disease accumulates more resistance mechanisms over time.
Combination strategies
Both drugs are increasingly used as part of triplet or quadruplet regimens rather than alone:
- Lenalidomide is commonly combined with a proteasome inhibitor (bortezomib, carfilzomib) and dexamethasone, and increasingly with daratumumab in newly diagnosed patients (the “quad” regimens like Dara-VRd)
- Pomalidomide is commonly combined with dexamethasone and an anti-CD38 antibody (daratumumab or isatuximab) in the relapsed setting, which has shown meaningfully better outcomes than pomalidomide-dexamethasone alone
Bottom line
Lenalidomide and pomalidomide are best understood as sequential tools in the myeloma treatment journey rather than competing first-choice options — lenalidomide is the earlier-line, more established standard (especially for maintenance after transplant), while pomalidomide exists specifically to provide continued IMiD-class benefit once lenalidomide resistance develops. The shared boxed warnings and REMS requirements mean the safety conversation is largely similar between them, while the practical differences — pomalidomide’s somewhat more pronounced neutropenia and its more favorable profile in renal impairment — become relevant considerations once a patient reaches the point of needing this next-line option. Your specific treatment history, current kidney function, and how your myeloma responded to lenalidomide will shape this conversation with your hematologist.
How does testing work
The REVLIMID REMS program exists because of a specific historical tragedy that fundamentally changed how thalidomide-related drugs are regulated — understanding that history explains why this isn’t ordinary prescribing caution, but a structurally different distribution system.
What REMS means
REMS stands for Risk Evaluation and Mitigation Strategy — a regulatory tool the FDA can require for drugs whose risks are serious enough that normal prescribing safeguards (a doctor’s judgment plus a standard pharmacy dispensing process) aren’t considered sufficient on their own. REMS programs vary in intensity; lenalidomide’s is one of the more restrictive versions, sometimes called “REMS with Elements to Assure Safe Use” (ETASU).
Why lenalidomide specifically needs this — the thalidomide history
Lenalidomide is structurally derived from thalidomide. In the late 1950s and early 1960s, thalidomide was prescribed — often for morning sickness — to pregnant women in dozens of countries before its teratogenic effects were understood. The result was thousands of infants born with severe limb deformities (phocomelia, where limbs are absent or severely shortened), along with other congenital abnormalities affecting the ears, eyes, heart, and internal organs. This remains one of the most significant drug safety failures in medical history and directly shaped modern pharmaceutical regulation, including the requirement for rigorous testing of teratogenic potential before approval.
When lenalidomide was developed decades later as a more potent and differently-tolerated derivative of thalidomide, animal studies confirmed it carries the same fundamental risk — a developmental monkey study showed limb abnormalities similar to those caused by thalidomide in humans. Given this direct mechanistic link to one of history’s most consequential teratogens, regulators required a distribution system specifically designed to make a repeat of that history structurally very difficult, rather than relying solely on physician and patient awareness.
What the REMS program actually requires
The program has several interlocking layers:
Prescriber certification — physicians must register with the program, complete specific training, and agree to follow defined protocols before they can prescribe lenalidomide at all.
Pharmacy certification — only pharmacies registered with the program can dispense it; lenalidomide cannot be filled at just any pharmacy the way most prescriptions can.
Patient registration — patients must enroll in the program, which includes counseling about the risks and required precautions.
Pregnancy testing protocol — for anyone of reproductive potential, two negative pregnancy tests are required before the first dose, followed by regular pregnancy testing throughout treatment (weekly during the first month, then less frequently if cycles are regular, or more frequently if periods are irregular).
Mandatory contraception — two reliable forms of contraception are required simultaneously throughout treatment and for a defined period after stopping, with very limited exceptions (such as confirmed surgical sterilization or abstinence, which must be verified rather than assumed).
Male patient requirements — because lenalidomide is present in semen, male patients — including those who have had a vasectomy — must agree to use condoms during any sexual contact with a person who could become pregnant.
Prescription timing limits — prescriptions are typically limited to no more than a 28-day supply, requiring renewed authorization rather than allowing long-term refills, which keeps the safety checkpoints active throughout treatment rather than only at the start.
Ongoing survey requirements — patients and prescribers periodically complete surveys confirming continued adherence to the safety requirements.
Why this differs from a typical “boxed warning” drug
Many drugs we’ve discussed in this conversation carry boxed warnings and require careful monitoring — but lenalidomide’s REMS program is structurally different. A boxed warning informs and cautions; it relies on the prescriber and patient to act on that information correctly. A REMS program with these elements actually restricts who can prescribe, who can dispense, and how much can be obtained at once, building safety checkpoints directly into the distribution chain rather than relying solely on individual judgment.
Why this matters practically for you as a patient
Understanding this distinction helps explain some practical realities of being on lenalidomide:
- You cannot simply transfer your prescription to any pharmacy — it must be REMS-certified
- You cannot get an early refill or a larger supply “to be safe” — the 28-day limit is a deliberate safety feature, not an inconvenience
- If you miss a required pregnancy test or survey, your next prescription fill may be delayed until you complete it — this isn’t bureaucratic friction, it’s the system working as designed
- If you travel, plan ahead — finding a REMS-certified pharmacy in a different location takes more effort than finding any general pharmacy
The broader principle
The REVLIMID REMS program reflects a hard-won lesson from one of medicine’s most serious historical failures: when a drug’s potential for harm is severe, irreversible, and specifically tied to a documented historical precedent, regulatory systems sometimes go beyond informing prescribers and patients to actively restricting how the drug moves through the healthcare system. This is precisely why the requirements can feel more demanding than for other serious medications — they were built in direct response to what happens when that level of caution isn’t present.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
